1 option
Development of antibody prodrug conjugates activated by legumain / Hans-Georg Lerchen.
- Format:
- Video
- Author/Creator:
- Lerchen, Hans-Georg, (Bayer AG, Germany), Speaker.
- Series:
- Henry Stewart talks. Biomedical & life sciences collection.
- The biomedical & life sciences collection, 2056-452X
- Language:
- English
- Subjects (All):
- Antibody-drug conjugates.
- Drug development.
- Antibodies, Monoclonal.
- Antineoplastic Agents.
- asparaginylendopeptidase.
- Cysteine Endopeptidases.
- Immunoconjugates.
- Prodrugs.
- TWEAK Receptor.
- Medical Subjects:
- Antibodies, Monoclonal.
- Antineoplastic Agents.
- asparaginylendopeptidase.
- Cysteine Endopeptidases.
- Immunoconjugates.
- Prodrugs.
- TWEAK Receptor.
- Physical Description:
- 1 videorecording (34 min., 49 sec.)
- Place of Publication:
- London : Henry Stewart Talks, 2021.
- System Details:
- video file
- Contents:
- Contents: Modular composition of antibody drug conjugates
- ADC mode of action
- TWEAK receptor as an ADC target
- Improvements to achieve stable antibody conjugation
- KSP inhibitors as ADC toxophores
- Legumain-cleavable antibody prodrug conjugates
- Conceptualization of Antibody Prodrug Conjugates (APDCs) to increase the therapeutic window.
- Notes:
- Description based on: online resource; title from PDF information screen (Henry Stewart Talks Business & Management Collection, viewed April 5, 2024).
- Animated audio-visual presentation with synchronized narration.
- Title from title frames.
- Publisher Number:
- 5267 Henry Stewart Talks
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.